Nephrotoxicity of concomitant use of tacrolimus and teicoplanin in allogeneic hematopoietic stem cell transplant recipients

Takehiko Mori, Takayuki Shimizu, Jun Kato, Taku Kikuchi, S. Kohashi, Yuya Koda, T. Toyama, M. Saburi, O. Iketani, Shinichiro Okamoto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Both tacrolimus and glycopeptide antibiotics are known to be nephrotoxic, and are often concomitantly given after hematopoietic stem cell transplantation (HSCT) or solid organ transplantation. The aim of this study is to evaluate the nephrotoxicity of concomitant use of tacrolimus and glycopeptide antibiotics in HSCT recipients. We retrospectively evaluated 67 patients who received intravenous tacrolimus and teicoplanin concomitantly for >4 days after allogeneic HSCT for hematologic diseases. Therapeutic drug monitoring (TDM) was performed in all patients for both tacrolimus and teicoplanin. The median age of the patients was 48 years (range: 16-62), and the median duration of the co-administration of tacrolimus and teicoplanin was 11 days (range: 4-40). The mean serum creatinine (sCr) level tended to be elevated after the co-administration (from 0.69 ± 0.26 to 0.75 ± 0.30 mg/dL; P = 0.08); however, a 2-fold or greater increase in sCr was observed only in 2 (3.0%) patients. Increased sCr was reversible, and no patient required hemodialysis. These results suggest that the incidence of clinically significant nephrotoxicity can be minimized if the TDM of each drug is properly applied.

Original languageEnglish
Pages (from-to)329-332
Number of pages4
JournalTransplant Infectious Disease
Volume16
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Teicoplanin
Tacrolimus
Hematopoietic Stem Cells
Hematopoietic Stem Cell Transplantation
Transplants
Creatinine
Glycopeptides
Drug Monitoring
Serum
Anti-Bacterial Agents
Hematologic Diseases
Organ Transplantation
Renal Dialysis
Transplant Recipients
Incidence
Pharmaceutical Preparations

Keywords

  • Nephrotoxicity
  • Serum creatinine
  • Tacrolimus
  • Teicoplanin
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Transplantation
  • Infectious Diseases
  • Medicine(all)

Cite this

@article{0fb7d761c32d4656a131ab553b6f7b70,
title = "Nephrotoxicity of concomitant use of tacrolimus and teicoplanin in allogeneic hematopoietic stem cell transplant recipients",
abstract = "Both tacrolimus and glycopeptide antibiotics are known to be nephrotoxic, and are often concomitantly given after hematopoietic stem cell transplantation (HSCT) or solid organ transplantation. The aim of this study is to evaluate the nephrotoxicity of concomitant use of tacrolimus and glycopeptide antibiotics in HSCT recipients. We retrospectively evaluated 67 patients who received intravenous tacrolimus and teicoplanin concomitantly for >4 days after allogeneic HSCT for hematologic diseases. Therapeutic drug monitoring (TDM) was performed in all patients for both tacrolimus and teicoplanin. The median age of the patients was 48 years (range: 16-62), and the median duration of the co-administration of tacrolimus and teicoplanin was 11 days (range: 4-40). The mean serum creatinine (sCr) level tended to be elevated after the co-administration (from 0.69 ± 0.26 to 0.75 ± 0.30 mg/dL; P = 0.08); however, a 2-fold or greater increase in sCr was observed only in 2 (3.0{\%}) patients. Increased sCr was reversible, and no patient required hemodialysis. These results suggest that the incidence of clinically significant nephrotoxicity can be minimized if the TDM of each drug is properly applied.",
keywords = "Nephrotoxicity, Serum creatinine, Tacrolimus, Teicoplanin, Therapeutic drug monitoring",
author = "Takehiko Mori and Takayuki Shimizu and Jun Kato and Taku Kikuchi and S. Kohashi and Yuya Koda and T. Toyama and M. Saburi and O. Iketani and Shinichiro Okamoto",
year = "2014",
doi = "10.1111/tid.12185",
language = "English",
volume = "16",
pages = "329--332",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Nephrotoxicity of concomitant use of tacrolimus and teicoplanin in allogeneic hematopoietic stem cell transplant recipients

AU - Mori, Takehiko

AU - Shimizu, Takayuki

AU - Kato, Jun

AU - Kikuchi, Taku

AU - Kohashi, S.

AU - Koda, Yuya

AU - Toyama, T.

AU - Saburi, M.

AU - Iketani, O.

AU - Okamoto, Shinichiro

PY - 2014

Y1 - 2014

N2 - Both tacrolimus and glycopeptide antibiotics are known to be nephrotoxic, and are often concomitantly given after hematopoietic stem cell transplantation (HSCT) or solid organ transplantation. The aim of this study is to evaluate the nephrotoxicity of concomitant use of tacrolimus and glycopeptide antibiotics in HSCT recipients. We retrospectively evaluated 67 patients who received intravenous tacrolimus and teicoplanin concomitantly for >4 days after allogeneic HSCT for hematologic diseases. Therapeutic drug monitoring (TDM) was performed in all patients for both tacrolimus and teicoplanin. The median age of the patients was 48 years (range: 16-62), and the median duration of the co-administration of tacrolimus and teicoplanin was 11 days (range: 4-40). The mean serum creatinine (sCr) level tended to be elevated after the co-administration (from 0.69 ± 0.26 to 0.75 ± 0.30 mg/dL; P = 0.08); however, a 2-fold or greater increase in sCr was observed only in 2 (3.0%) patients. Increased sCr was reversible, and no patient required hemodialysis. These results suggest that the incidence of clinically significant nephrotoxicity can be minimized if the TDM of each drug is properly applied.

AB - Both tacrolimus and glycopeptide antibiotics are known to be nephrotoxic, and are often concomitantly given after hematopoietic stem cell transplantation (HSCT) or solid organ transplantation. The aim of this study is to evaluate the nephrotoxicity of concomitant use of tacrolimus and glycopeptide antibiotics in HSCT recipients. We retrospectively evaluated 67 patients who received intravenous tacrolimus and teicoplanin concomitantly for >4 days after allogeneic HSCT for hematologic diseases. Therapeutic drug monitoring (TDM) was performed in all patients for both tacrolimus and teicoplanin. The median age of the patients was 48 years (range: 16-62), and the median duration of the co-administration of tacrolimus and teicoplanin was 11 days (range: 4-40). The mean serum creatinine (sCr) level tended to be elevated after the co-administration (from 0.69 ± 0.26 to 0.75 ± 0.30 mg/dL; P = 0.08); however, a 2-fold or greater increase in sCr was observed only in 2 (3.0%) patients. Increased sCr was reversible, and no patient required hemodialysis. These results suggest that the incidence of clinically significant nephrotoxicity can be minimized if the TDM of each drug is properly applied.

KW - Nephrotoxicity

KW - Serum creatinine

KW - Tacrolimus

KW - Teicoplanin

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=84897958007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897958007&partnerID=8YFLogxK

U2 - 10.1111/tid.12185

DO - 10.1111/tid.12185

M3 - Article

C2 - 24494811

AN - SCOPUS:84897958007

VL - 16

SP - 329

EP - 332

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

IS - 2

ER -